Front Cover.
Half Title Page.
Editorial Board.
Title Page.
Copyright Page.
Contents.
List of Entries.
Reader's Guide.
1: About the Editors.
Contributors.
Introduction.
2: Abstinence Violation Effect.
3: Acamprosate.
4: Acceptance and Commitment Therapy.
5: Access to Recovery.
6: Addiction, Models of.
7: Addiction Severity Index.
8: Addiction Technology Transfer Centers.
9: Adolescents, Substance Abuse and Treatment.
10: Adult Children of Alcoholics.
11: Al-Anon.
12: Alateen.
13: Alcohol.
14: Alcoholic Personality.
15: Alcoholics Anonymous.
16: Alcohol-Induced Disorders.
17: Alcoholism.
18: Alcohol Marketing.
19: Alcohol-Related Birth Defects.
20: Alcohol Testing.
21: Alcohol Use Disorders Identification Test.
22: Alternative Activities.
23: American Society of Addiction Medicine.
24: Amotivational Syndrome.
25: Amphetamines.
26: Amyl Nitrite.
27: Anabolic Steroids.
28: Anorexia Nervosa.
29: Antabuse (Disulfiram).
30: Antidepressant Drugs.
31: Antipsychotic Drugs.
32: Antiseizure Drugs.
33: Antisocial Personality Disorder.
34: Anxiety Disorders.
35: Anxiolytic Drugs.
36: Assessment.
37: Assessment Instruments.
38: Athletes and Drug Use.
39: Attention Deficit Hyperactivity Disorder.
40: Aversive Therapy.
41: Barbiturates.
42: Behavioral Couples Therapy.
43: Behavioral Risk Factor Surveillance System.
44: Benzodiazepines.
45: Big Book, The.
46: Bill W..
47: Binge Drinking.
48: Biopsychosocial Model of Addiction.
49: Blood Alcohol Concentration.
50: Borderline Personality Disorder.
51: Brain Chemistry and Addiction.
52: Brief Interventions.
53: Brief Strategic Family Therapy.
54: Bulimia Nervosa.
55: Buprenorphine.
56: Business Improvement Practices.
57: Caffeine.
58: Cage Screening Instrument.
59: Cannabis Youth Treatment Study.
60: Cenaps Model.
61: Center for Substance Abuse Prevention.
62: Center for Substance Abuse Treatment.
63: Centers for the Application of Prevention Technologies.
64: Central Nervous System Depressants.
65: Central Nervous System Stimulants.
66: Certification and Licensing.
67: Children of Alcoholics.
68: Chronicity.
69: Client Engagement.
70: Client/Treatment Matching.
71: Clinical Supervision of Addiction Counselors.
72: Club Drugs.
73: Cocaine and Crack.
74: Cocaine Anonymous.
75: Codependency.
76: Coercion and Treatment.
77: Cognitive Behavioral Therapy.
78: Cognitive-Social Learning Model.
79: College on Problems of Drug Dependence.
80: College Students, Alcohol Use and Abuse.
81: College Students, Drug Use and Abuse.
82: Combine Study.
83: Community-Based Processes.
84: Community Reinforcement and Family Training.
85: Community Reinforcement Approach.
86: Comprehensive Drug Abuse Prevention and Control Act.
87: Confidentiality.
88: Contingency Management.
89: Continuum of Care.
90: Co-Occurring Disorders.
91: Counseling Approaches.
92: Court-Mandated Treatment.
93: Covert Sensitization.
94: Craving.
95: Crime and Substance Abuse.
96: Criminal Justice Populations.
97: Cross-Addictions.
98: Cultural Aspects.
99: Decriminalization.
100: Demand Reduction.
101: Denial.
102: Depression.
103: Detoxification.
104: Diagnosis.
105: Diagnostic and Statistical Manual of Mental Disorders.
106: Disabilities, Issues in Prevention and Treatment.
107: Discrimination, Addicted and Recovering Individuals.
108: Disease Concept.
109: Double Trouble.
110: Driving Under the Influence.
111: Drug Abuse Resistance Education.
112: Drug Abuse Screening Test.
113: Drug Abuse Treatment Outcome Studies.
114: Drug Abuse Warning Network.
115: Drug Courts.
116: Drug-Free Schools and Communities Act.
117: Drug Laws, History of.
118: Drugs, Classification of.
119: Drug Testing.
120: Drug Use, History of.
121: Dry Drunk Syndrome.
122: Dual Relationships.
123: Economic Costs of Alcohol and Drug Abuse.
124: Ecstasy.
125: Elderly Populations, Treatment Issues.
126: Electronic Health Records.
127: Employee Assistance Program.
128: Enabling.
129: Environmental Approaches.
130: Ethical Standards for Addiction Professionals.
131: Ethics.
132: Evidence-Based Prevention.
133: Evidence-Based Prevention and Treatment, Dissemination and Adoption of.
134: Evidence-Based Treatment.
135: Expectancies.
136: Experimental Substance Use.
137: Family Behavior Therapy.
138: Family Therapy.
139: Fentanyl.
140: Fetal Alcohol Syndrome.
141: Fetal Effects of Alcohol and Other Drugs.
142: Fidelity of Prevention Programs.
143: Gamblers Anonymous.
144: Gambling, Pathological.
145: Gambling, Problem.
146: Gateway Drugs Theory.
147: Gay, Lesbian, Bisexual, and Transgender Issues.
148: Gender Issues.
149: Genetic Aspects of Addiction.
150: Grief, Loss, and Substance Abuse.
151: Group Therapy and Counseling.
152: Hallucinogens.
153: Harm Reduction, Public Health.
154: Harm Reduction Psychotherapy.
155: Health Care System and Substance Abuse.
156: Health Insurance Portability and Accountability Act.
157: Hepatitis C.
158: Heroin.
159: High-Risk Behaviors.
160: High-Risk Situations.
161: HIV/AIDS.
162: Homeless, Substance Abuse and Treatment.
163: Illicit and Illegal Drugs.
164: Impaired Professionals.
165: Indian Health Services.
166: Information Dissemination.
167: Informed Consent.
168: Inhalants.
169: Injection Drug Use.
170: Institute of Medicine Classification System.
171: Insurance Parity.
172: International Coalition for Addiction Studies Education.
173: Internet Addiction.
174: Inventory of Drinking Situations.
175: Jellinek, E. M. (1890-1963).
176: Johnson Model Intervention.
177: Join Together.
178: Legal Action Center.
179: Legalization of Drugs.
180: Levo-Alpha Acetyl Methadol.
181: Marijuana.
182: Maternal Drug Use.
183: Matrix Model.
184: Medical Consequences.
185: Medical Use of Marijuana.
186: Mentoring.
187: Methadone.
188: Methadone Maintenance Treatment.
189: Methamphetamine.
190: Methods of Drug Administration.
